Xylem (XYL)
(Delayed Data from NYSE)
$143.32 USD
+0.64 (0.45%)
Updated May 17, 2024 04:00 PM ET
After-Market: $143.27 -0.05 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$143.32 USD
+0.64 (0.45%)
Updated May 17, 2024 04:00 PM ET
After-Market: $143.27 -0.05 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Zacks News
Headquartered in Rye Brook, NY, Xylem Inc. is one of the leading providers of water solutions worldwide. The company is involved in the full water-process cycle, including collection, distribution and returning of water to the environment. It has significant presence in the United States, the Asia Pacific, Europe and various other nations. The company reports business operations under three segmental heads — Water Infrastructure, Sensus and Applied Water.
Xylem (XYL) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of -37.84% and -1.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q1 results are expected to reflect the adverse impacts of the uncertainties caused by the coronavirus outbreak. But healthy balance sheet and cost actions might have aided.
Analysts Estimate Xylem (XYL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How are Industrial Product Stocks Placed for Q1 Earnings?
by Payal Jalan
The coronavirus outbreak mars earnings and revenue prospects for many companies under the Industrial Products sector. Collective results for the first quarter of 2020 might be lackluster.
Drab Near-Term Prospects for Industrial Manufacturing Stocks
by Avisekh Bhattacharjee
The Manufacturing - General Industrial industry is facing coronavirus-related issues, job losses & other problems. Technological advancement in manufacturing processes will likely be a growth driver.
NPO vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NPO vs. XYL: Which Stock Is the Better Value Option?
Flowserve (FLS) Withdraws Annual View on Coronavirus Concerns
by Zacks Equity Research
Flowserve (FLS) withdraws guidance for 2020, owing to uncertainties in the end-markets on the impacts of the coronavirus outbreak.
Xylem (XYL) Withdraws Guidance Based on Coronavirus Concerns
by Zacks Equity Research
Xylem (XYL) withdraws guidance for the first quarter and 2020, owing to the coronavirus outbreak.
NPO vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
NPO vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Declines 18% YTD: What's Hurting the Stock?
by Zacks Equity Research
Xylem (XYL), with an 18% decline in shares so far in 2020, faces headwinds from the coronavirus outbreak, softness in commercial and industrial markets, and soft orders.
Xylem (XYL) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Reasons Why You Should Avoid IDEX (IEX) Stock for Now
by Zacks Equity Research
IDEX (IEX) is exposed to challenging end markets, unfavorable movements in foreign currencies, and the impacts of variable compensation, tax rate and growth investments.
Here's Why Investors Should Ignore Xylem (XYL) Stock for Now
by Zacks Equity Research
Xylem (XYL) is exposed to challenging end markets, issues related to Coronavirus, soft orders and others. The headwinds are expected to adversely impact its results in the first half of 2020.
Xylem (XYL) Q4 Earnings Estimates Meet, Dividend Rate Rises
by Zacks Equity Research
Xylem's (XYL) Q4 earnings came in line but the same improves year over year on lower interest expenses. The company declares an 8% raise in quarterly dividend rate.
Xylem (XYL) Matches Q4 Earnings Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Xylem's (XYL) Q4 is likely to have gained from the emerging markets business, productivity moves and positive pricing. But soft volumes, end-market weakness and lower margin mix might have ailed.
Xylem (XYL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Softness in End Markets and Forex Woes to Hurt Xylem (XYL)
by Zacks Equity Research
Xylem's (XYL) 2019 performance will likely suffer from softness in certain end markets and unfavorable movements in foreign currencies. High costs and huge debts are other concerns.
Dull Near-Term Prospects for Industrial Manufacturing Stocks
by Zacks Equity Research
The Manufacturing - General Industrial industry is facing material cost inflation issues. In the long term, technological advancement in manufacturing processes is likely to be a major growth driver.
Xylem (XYL) Meets Q3 Earnings Estimates, Lowers '19 View
by Zacks Equity Research
Xylem's (XYL) third-quarter 2019 earnings meet estimates but rise year over year on solid organic sales and improved margins. The company lowers 2019 earnings projection.
Xylem (XYL) Matches Q3 Earnings Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 0.00% and -2.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) third-quarter 2019 results are expected to reflect benefits of strengthening end markets, exposure to emerging markets and product innovation. Cost and forex woes might have been drags.
Xylem (XYL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEX's Diversified Business and Buyouts Aid Despite Forex Woes
by Zacks Equity Research
IDEX (IEX) gains from a diversified business structure, solid product offerings, acquired assets and shareholder-friendly policies. Geopolitical uncertainties and forex woes are headwinds.
Forget Xylem, Invest in These 4 Industrial Stocks Instead
by Zacks Equity Research
Global uncertainties and tariffs weigh on the Industrial Products sector while technological advancements and e-retailing are positives for the space. We present four stocks that are investment worthy.